To bridge this gap in our understanding, researchers have been actively pursuing innovative methodologies to profile S-nitrosylated proteins on a proteome-wide scale. A particularly promising advance in this area involves the development of a novel chemical probe named SNO-TRAP. This probe incorporates a triphenylphosphine thioester linked to a biotin molecule via a polyethylene glycol (PEG) spacer. The design of SNO-TRAP allows for the selective enrichment of S-nitrosylated proteins in complex biological samples, thus paving the way for enhanced analytical capacity using mass spectrometry (MS). With SNO-TRAP, researchers can precisely identify the S-nitrosoproteome across various tissues, providing a broad view of how S-nitrosylation may affect physiological and pathological processes.

In a groundbreaking protocol detailed in a recent publication, the process of isolating and profiling S-nitrosylated proteins using SNO-TRAP in conjunction with mass spectrometry is outlined comprehensively. The protocol begins with meticulous tissue sample preparation, ensuring that the proteins of interest are appropriately handled to preserve their post-translational modifications. Following this, the synthesis of the SNO-TRAP probe is performed under an inert argon atmosphere. Such a controlled environment is crucial as it minimizes oxidative damage and ensures the integrity of the reactive components involved in the SNO tagging process.

Once the SNO-TRAP probe has been synthesized, the next step involves the in situ labeling of S-nitrosylated proteins within the sample. The chemical reaction facilitated by the SNO-TRAP probe leads to the formation of a disulfide–iminophosphorane, which serves as a unique labeling tag for the modified proteins. This specificity not only allows for the effective capture of S-nitrosylated species but also enhances downstream analytical accuracy by removing non-target proteins that could obscure the detection of SNO modifications.

Post-labeling, the subsequent analysis involves digesting the chemically tagged proteins, followed by selective capture using streptavidin, which binds tightly to the biotin component of the SNO-TRAP. Such techniques enable researchers to concentrate the S-nitrosylated peptides, significantly improving the signal-to-noise ratio for subsequent mass spectrometric analysis. The liberated free cysteine residues can then undergo relabeling with N-ethylmaleimide, further ensuring that only the relevant peptides are quantified in the final analysis.

This robust method not only enriches S-nitrosylated peptides across various tissues, including the human and mouse brain but also facilitates a thorough, proteome-wide identification of these modifications. The dynamic nature of S-nitrosylation, often characterized by its transient expression, makes such comprehensive profiling both a significant challenge and a monumental achievement in the field of proteomics. The quantification of S-nitrosylated proteins via Orbitrap mass spectrometry results in invaluable insights into the functional consequences of these modifications on cellular behavior, potentially identifying new therapeutic targets for disease intervention.

The timeline for the entire process, from synthesis of the SNO-TRAP probe to the final mass spectrometric measurements, spans approximately five days for the synthesis phase, followed by an additional 2 to 2.5 days dedicated to sample preparation. The quantification and analysis require about five more days, making the comprehensive analysis a time-intensive yet worthwhile endeavor that promises to shed light on the complexities of protein S-nitrosylation.

By employing these innovative strategies, researchers are poised to unveil the intricacies of the S-nitrosoproteome, revolutionizing our understanding of how S-nitrosylation influences human health and disease. As the world of biomedical research continues to evolve, the methods developed for profiling S-nitrosylated proteins not only hold promise for advancing basic science but also pave the way for novel therapeutic strategies aimed at mitigating a range of pathological conditions. Ultimately, the work surrounding the SNO-TRAP probe exemplifies the intersection of cutting-edge chemistry and biology, offering hope for breakthroughs that can change the landscape of disease treatment and management.

This ongoing journey into the world of protein modifications illustrates the complexity of biological systems, where subtle changes can lead to significant functional consequences. As more researchers adopt and refine these methodologies, the pivotal role of S-nitrosylation in cellular function and disease will undoubtedly garner the attention it deserves, ushering in a new era of precision medicine. With each advancement, the scientific community moves one step closer to fully unraveling the enigmatic nature of S-nitrosylation and its potential implications for the future of health care.

The detailed exploration of S-nitrosylation through SNO-TRAP exemplifies the passion driving research forward. As researchers continue to adopt such innovative techniques, we can anticipate a heightened appreciation for the subtle yet profound ways in which protein modifications govern cellular dynamics. The future looks bright for the quest to understand these essential biological processes, heralding a new chapter in the quest for effective disease-modifying therapies.

In conclusion, the methodology outlined in this study not only illuminates the path toward understanding S-nitrosylation but also serves as a template for future research endeavors. The capabilities of SNO-TRAP, in conjunction with mass spectrometry, represent a significant advancement in proteomics, providing a powerful tool for scientists seeking to unveil the complexities of protein function in health and disease. As ongoing and future research builds upon this foundation, the landscape of molecular biology will undoubtedly reveal more about the fundamental processes that sustain life.

As we continue to explore the implications of O-nitrosylation in the context of various diseases, the insights garnered from such pioneering research may be instrumental in the development of targeted therapies that leverage these molecular mechanisms for better health outcomes. The potential of S-nitrosylation in regulating cellular behavior offers a glimpse into a transformative future in biomedical science.

Indeed, the advancements enabled by the SNO-TRAP technique open doors for exciting research possibilities, enhancing our understanding of protein modifications and their roles in disease progression. Through rigorous investigation and innovation, the scientific community stands poised to unlock the therapeutic potential of S-nitrosylation, further blending the worlds of chemistry and biology. As we navigate this promising intersection, the pursuit of knowledge remains at the forefront of scientific inquiry.

Subject of Research: Profiling of S-nitrosylated proteins using the SNO-TRAP probe and mass spectrometry detection.

Article Title: Proteome-wide profiling of S-nitrosylated proteins using the SNO-TRAP probe and mass spectrometry-based detection.

Article References:

Yang, H., Amal, H., Tannenbaum, S.R. et al. Proteome-wide profiling of S-nitrosylated proteins using the SNO-TRAP probe and mass spectrometry-based detection. Nat Protoc (2025). https://doi.org/10.1038/s41596-025-01282-1

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41596-025-01282-1

Keywords: S-nitrosylation, proteomics, mass spectrometry, SNO-TRAP, post-translational modification.

Proteins serve as the fundamental workhorses of the biological system, orchestrating myriad cellular processes including tissue growth, metabolic regulation, and immune defense. However, the functionality of proteins is not solely determined by their amino acid sequence; it is extensively modulated by chemical modifications introduced after the protein has been synthesized. These modifications, collectively known as post-translational modifications, involve the covalent attachment of various chemical groups such as phosphates, sugars, or acetyl groups. These PTMs finely tune protein activity, stability, localization, and interactions, thereby dictating the broader cellular response and health outcomes.

PTMs represent critical regulatory nodes within the proteome, directing signaling pathways and cellular machinery in both normal and pathological states. Dysfunctional PTMs have been directly implicated in the etiology of numerous complex diseases, including malignancies, cardiovascular conditions, and degenerative neurological disorders. A mutation in the DNA sequence can disrupt normal PTM patterns by abolishing a modification site, creating ectopic sites, or perturbing the surrounding amino acid environment, thereby derailing protein function and precipitating disease. Therefore, precisely pinpointing PTM sites and understanding mutation-driven alterations are paramount to elucidating disease mechanisms.

Addressing this challenge, the Baylor research team led by Dr. Bing Zhang developed DeepMVP—a deep learning framework meticulously trained to identify PTM sites across the human proteome and predict how mutations reshape these sites. The model was constructed using a novel dataset named PTMAtlas, which represents a comprehensive and rigorously curated collection of 397,524 verified PTM sites derived from the systematic reanalysis of 241 publicly available proteomic datasets. Focusing on six prevalent PTM types, including phosphorylation and glycosylation, PTMAtlas provides a densely annotated resource that dramatically surpasses existing databases in both breadth and accuracy.

DeepMVP’s architecture leverages modern deep neural networks capable of discerning subtle sequence patterns indicative of PTM sites, integrating contextual biochemical properties to enhance predictive power. This approach enables not only precise site identification but also the assessment of how specific amino acid substitutions may enhance or diminish PTM occurrence. The model’s flexibility extends to non-human proteins, effectively predicting PTM sites in viral proteins such as those from the SARS-CoV-2 virus, highlighting its wide utility across biomedical research domains.

Benchmarking DeepMVP against eight state-of-the-art computational tools revealed a clear superiority in performance. Evaluation on a curated set of 235 experimentally validated mutation-PTM pairs demonstrated an impressive 81% accuracy in pinpointing exact PTM sites. More strikingly, DeepMVP correctly predicted the directional change—increase or decrease—of PTM levels caused by mutations in 97% of the cases. These results underscore DeepMVP’s effectiveness in interpreting the functional repercussions of genetic variation at the post-translational level.

The implications of DeepMVP’s predictive capabilities extend far beyond academic interest. By enabling a high-resolution view of how mutations perturb PTM landscapes, this tool offers a powerful platform for the identification of novel therapeutic targets and the design of precision medicine approaches. For example, in cancer biology, understanding aberrant PTM patterns linked to oncogenic mutations may drive the development of targeted inhibitors that restore normal cellular signaling. Similarly, in neurological and cardiovascular diseases, identifying mutation-induced PTM changes could illuminate pathophysiological processes hitherto obscured in genetic studies.

DeepMVP is freely accessible to the global research community, fostering collaborative efforts to exploit its potential across various health disciplines. This open-access availability ensures that scientists investigating disease genetics, drug discovery, and molecular biology can integrate DeepMVP predictions into their workflows, accelerating the translation of genetic insights into tangible clinical interventions.

Complementing the AI model, PTMAtlas stands as a monumental achievement, synthesizing extensive proteomic data into one unified framework. Its creation involved the harmonization of heterogeneous datasets, rigorous quality control measures, and sophisticated bioinformatic pipelines. This assembly provides an unprecedented foundation for future studies in proteomics, molecular evolution, and systems biology, enabling researchers to navigate the complexity of protein modifications with newfound clarity.

The Baylor team acknowledges significant support from various funding bodies, including the National Cancer Institute (NCI) and the Cancer Prevention and Research Institutes of Texas, underscoring the critical role of sustained investment in biomedical innovation. Additionally, computational resources such as the NVIDIA Titan Xp GPU facilitated the model’s training and optimization, reflecting the increasingly interdisciplinary nature of modern bioscience combining biology, computer science, and engineering.

Looking ahead, the researchers envision expanding DeepMVP’s capabilities to encompass additional PTM types and incorporating structural protein information to further refine predictions. Coupled with advances in high-throughput proteomics and functional genomics, such enhancements could revolutionize our capacity to decode the molecular underpinnings of human diseases.

In summary, the deployment of DeepMVP marks a seminal leap in the application of AI to biomedical research, offering a powerful avenue to decode the molecular grammar that links genetic variation to functional protein changes. This work not only deepens our understanding of cellular regulation at the molecular level but also propels the potential for innovative therapeutic strategies targeting post-translational modifications, thus opening new frontiers in precision medicine.

Subject of Research: People

Article Title: DeepMVP: deep learning models trained on high-quality data accurately predict PTM sites and variant-induced alterations

News Publication Date: 26-Aug-2025

Web References: https://www.nature.com/articles/s41592-025-02797-x

References:
Zhang, B., Wang, C., Wen, B., Li, K., Han, P., Holt, M. V., Savage, S. R., Lei, J. T., Dou, Y., Shi, Z., & Li, Y. DeepMVP: deep learning models trained on high-quality data accurately predict PTM sites and variant-induced alterations. Nature Methods, 26 August 2025. DOI: 10.1038/s41592-025-02797-x

Image Credits: Baylor College of Medicine

Keywords: Applied sciences and engineering, Applied mathematics, Computer science, Health and medicine